$Corvus Pharmaceuticals (CRVS.US)$
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Corvus Pharmaceuticals announced new preclinical data showing that soquelitinib, their lead ITK inhibitor, could potentially prevent lung damage, inflammation, and pulmonary hypertension caused by systemic sclerosis. The study used Fra-2 transgenic mice, which mirror human systemic sclerosis features. After seven weeks of oral soquelitinib...

$XIAOMI-W (01810.HK)$ The current status of Xiaomi is fully in line with the below characteristics.
When buying stocks, investors are essentially investing in the following aspects of a company:
1. Future Growth Potential
• The growth prospects of the industry the company operates in (e.g., emerging sectors like renewable energy or artificial intelligence).
• Whether the company has a clear development strategy, innovative capacity, and expansion plan...

$Forte Biosciences (FBRX.US)$
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
Forte Biosciences (NASDAQ: FBRX) has secured an oversubscribed $53 million private placement from leading healthcare institutional investors, including OrbiMed, Janus Henderson Investors, and Tybourne Capital Management. The funding will support the clinical advancement of FB102 across autoim...